title: Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Piccini
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Anne S
authors.initials: AS
authors.lastname: Hellkamp
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Washam
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Richard C
authors.initials: RC
authors.lastname: Becker
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Günter
authors.initials: G
authors.lastname: Breithardt
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Scott D
authors.initials: SD
authors.lastname: Berkowitz
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Halperin
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Graeme J
authors.initials: GJ
authors.lastname: Hankey
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Werner
authors.initials: W
authors.lastname: Hacke
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Mahaffey
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Nessel
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Singer
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Keith A A
authors.initials: KA
authors.lastname: Fox
authors.affiliation: From the Duke Clinical Research Institute (J.P.P., A.S.H., M.R.P.) and Duke Heart Center (J.P.P., J.B.W., M.R.P.), Duke University Medical Center, Durham, NC; University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Hospital of the University of Münster, Germany (G.B.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (G.J.H.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Department of Medicine, Stanford University, CA (K.W.M.); Janssen Pharmaceutical Research and Development, Raritan, NJ (C.C.N.); Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
authors.forename: Manesh R
authors.initials: MR
authors.lastname: Patel
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D019338:Polypharmacy; D000069552:Rivaroxaban; D020521:Stroke / Q000188:drug therapy; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D014859:Warfarin; D000069552:Rivaroxaban